Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | TLR2 | O60603 | 2/20 | 0.50 |
| ▸ | MDM2 | Q00987 | 7/20 | 0.49 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30945367 | 1.00 | MDM4 (0.52) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL20356921 | 1.00 | MDM4 (0.52) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL22442043 | 1.00 | MDM4 (0.52) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL30945373 | 1.00 | MDM4 (0.52) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL30945372 | 1.00 | MDM4 (0.52) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL20356919 | 1.00 | MDM4 (0.52) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL25356638 | 0.99 | MDM4 (0.53) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL25356643 | 0.99 | MDM4 (0.53) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL25356844 | 0.97 | MDM4 (0.53) | MDM4TP53TLR2MDM2CASP3 | |
| SCHEMBL25356848 | 0.97 | MDM4 (0.53) | MDM4TP53TLR2MDM2CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | BACOBA AG (CH) | 2026-02-19 | — | — | US | disclosed |
| US-20240174714-A1 | TREATMENT OF SKIN DISORDERS | BACOBA AG (CH) | 2024-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240174714-A1 | TREATMENT OF SKIN DISORDERS | HRH4, NR1H4, NR1H3 | MDM4 3823/4885TP53 4245/4885TLR2 619/4885 |
| US-20260049101-A1 | TOPICAL TREATMENT OF SKIN CANCER USING OLIGOPEPTIDES | NGLY1, MC1R, EGFR | MDM4 2280/4885TP53 190/4885TLR2 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.